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Vitamin C (ascorbic acid, ascorbate) is a major water soluble
antioxidant with a variety of biological functions. It plays roles in
collagen and carnitine synthesis and may be important in main-
taining proper immune cell function (Goldschmidt, 1991; Penn
et al, 1991). In rodents, vitamin C protects normal tissues from the
oxidative damage associated with chemotherapy and radiation
(Fujita et al, 1982; Okunieff and Suit, 1987). These and other
observations have created interest in using vitamin C as an
adjuvant treatment for cancer (Henson et al, 1991). 
While vitamin C commonly functions as an antioxidant, it can
also act as a pro-oxidant by converting free radicals into hydrogen
peroxide, a molecule that can damage cell membranes and DNA 
if not neutralized by the cellular enzyme catalase (Koch and
Biaglow, 1978). At sufficient concentrations, vitamin C can
produce cytotoxic levels of hydrogen peroxide. Tumour cells are
often catalase deficient and therefore more sensitive than normal
to hydrogen peroxide (Benade et al, 1969). Vitamin C accumulates
in solid tumours at concentrations higher than those in surrounding
normal tissue (Langemann et al, 1989; Agus et al, 1999). This has
raised concerns that vitamin C may provide tumours with anti-
oxidant protection from traditional therapeutic modalities (Raloff,
2000). However, vitamin C may be useful as an anti-cancer agent
if cytotoxic ascorbate concentrations can be achieved in tumours
(Riordan et al, 1995). 
Experiments in rodents suggest that ascorbate administration
increases host survival times and inhibit tumour growth (Varga
and Airoldi, 1983; Tsao et al, 1988). Clinical trials with vitamin C
have yielded mixed results. In 2 Scottish studies, terminal cancer
patients given intravenous vitamin C (10 g day–1) showed longer
survival times than historical controls (Cameron and Campbell,
1974; Cameron and Pauling, 1976). A Japanese study yielded
similar results (Murata et al, 1982), but 2 double-blind studies at
the Mayo clinic using oral vitamin C (10 g day–1) showed no
benefit (Creagan et al, 1979; Moertel et al, 1985). Oral vitamin C
supplementation is unlikely to produce plasma ascorbate levels
sufficient to kill tumour cells directly (Riordan et al, 1995).
Intravenous vitamin C at higher doses has been effective in
individual cases (Riordan et al, 1990, 1998; Jackson et al, 1995). 
We tested the anti-cancer efficacy of vitamin C and other
antioxidants (vitamin K3, lipoic acid, phenyl ascorbate) using the
SW620 hollow fibre solid tumour (HFST) model, a heterogeneous
in vitro model that shares important traits with solid tumour
microregions (Casciari et al, 1994). We also examined the effect of
vitamin C on doxorubicin efficacy in HFST. Finally, we measured
ascorbate concentrations in human plasma during and intravenous
infusions to determine if cytotoxic levels were clinically achiev-
able. 
MATERIALS AND METHODS 
Cell culture 
SW620 human colon carcinoma cells (ATCC, Rockville, MD)
were grown in RPMI medium (Irvine Scientific, Santa Anna, CA)
supplemented with 105 U l–1 penicillin, 105 mg l–1 streptomycin,
10% fetal bovine serum (Sigma Chemical Co, St Louis, MO) and
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2 mM glutamine (Irvine Scientific, Santa Anna, CA). The cells
were incubated at 37˚C with a gas phase of 5% CO2 in air at 100%
relative humidity. Cells were passaged weekly, and replaced with
fresh cells from liquid nitrogen storage every 6 months. Cells were
harvested from monolayer cultures using a standard trypsin and
EDTA solution (Irvine Scientific, Santa Anna, CA). The following
additional cell lines, all from ATCC (Rockville, MD), were used in
monolayer dose–response experiments: CCD-18Co (human colon
fibroblast), CCD-25Sk (human skin fibroblast), CCD-18Lu (human
lung fibroblast), SK-Mel (human melanoma), Mia PaCa (human
pancreatic carcinoma), and MCF-7 (human breast carcinoma).
These cells were maintained in Dulbecco’s Modified Eagle
Medium (Irvine Scientific, Santa Anna, CA) supplemented with
serum, glutamine and antibiotics as described above. 
Reagents 
Sodium ascorbate, lipoic acid (6,8-thioctic acid), doxorubicin,
vitamin K3 (menadione sodium bisulfate) were obtained from
Sigma Chemical Co (St Louis, MO). The sodium salt of lipoic 
acid was prepared by mixing lipoic acid (0.1 M) with sodium
bicarbonate (0.1 M) in de-ionized water. The solution was then
lyophilized to recover a yellow-green powder. Analysis using an
UV spectrophotometer indicated that the sodium salt had the same
maximum absorbance, 330 nm, as lipoic acid. Phenyl ascorbate
was kindly provided by Dr Kandatege Wimalasena (Wichita State
University, Wichita, KS). In combination studies, concentration
ratios were selected so that the concentration of the second agent
would be sub-lethal when that of ascorbate was in the effective
range. The following mass ratios were used: a 40:1 ratio of ascor-
bate to vitamin K3; a 100:1 ratio of ascorbate to lipoic acid; a 10:1
ratio of ascorbate to the sodium salt of lipoic acid; and a 
10 000:1 ratio of ascorbate to doxorubicin. In the case of lipoic
acid, the ratio was restricted by poor solubility. 
Cell growth inside hollow fibres 
SW620 HFST were grown as described previously (Casciari et al,
1994). Briefly, 500 mm internal diameter PVDF hollow fibres with
a 5 ´ 105 Dalton molecular mass cutoff (Spectrum Laboratories,
Laguna Hills, CA) were soaked in 70% ethanol for one week and
then soaked in tissue culture medium with serum for at least one
day. These fibres were then injected with a suspension of 107
SW620 cells ml–1 and heat sealed at roughly 1 cm intervals. After
3 days of incubation, the growth medium was replenished and 
the dishes were transferred to a Rotomix 50800 orbital shaker
rotating at 120 rpm (Thermolyne, Duboque, IA). Medium was
replenished every other day thereafter. SW620 HSFT were used 
in dose–response experiments after either 2 days (sparse) or 
10 days (solid). 
Dose–response experiments 
Dose–response experiments using SW620 HFST were conducted
as described previously (Casciari et al, 1994). Individual fibres
were transferred to 12-well plates (Becton Dickinson, Franklin
Lanes, NJ) containing 1 ml growth medium. Reagents were added
at various concentrations and the fibres were incubated for 2 days.
Cells were then extruded from the fibres, dispersed using a trypsin
and EDTA solution, counted (Model ZM, Coulter Corporation,
Miami, FL), and seeded in 96-well plates using a concentration of
5000 cells per well. After 6 days, the cells were fixed and stained
with the protein marker sulforhodamine B (SRB) (Sigma
Chemical Co, St Louis, MO). The stain was then dissolved in 
10 mM Tris and the absorbance at 565 nm was determined using
an Emax microplate reader (Molecular Devices, Sunnyvale, CA).
To determine LC50, the concentration at which the surviving frac-
tion is 50%, dose–response data from replicate experiments were
pooled and fit to a sigmoidal curve as described previously
(Casciari et al, 1994). All data fits were carried out with the
program KaleidaGraph (Synergy Software, Reading, PA), which
also provided standard errors estimates for LC50. To assess synergy
in combination therapy, the ascorbate LC50 of the combination
treatment was compared to that of a hypothetical ‘additive’
survival curve. The ‘additive’ curve was generated by multiplying
surviving fractions for ascorbate treatment alone to those, at
appropriate concentrations, for treatment with the other agent. In
experiments with cell monolayers, cells were seeded in 96-well
plates at concentrations of either 6 ´ 103 cells per well (exponen-
tial) or 24 ´ 103 cells per well (confluent) in 100 ml growth
medium. Various concentrations of ascorbate or lipoic acid were
added to the wells and the cells were incubated for 3 days. At this
time, cells were fixed and the cell number was determined using
the SRB assay. LC50 values were determined as described above. 
Apoptosis assays 
The extent of apoptosis in ascorbate-treated and -untreated HFST
was determined by dual staining with FITC conjugated annexin V
(AV) and propidium iodide (PI). Annexin V has a natural affinity
for phospholipid phosphatidylserine, a membrane molecule that
trans-locates from the intracellular side of the membrane to the
extracellular side soon after the initiation of apoptosis. HFST were
treated for 2 days with various concentrations of ascorbate as
described above. Cells were then collected from the hollow fibres.
Some were seeded in 96-well plates to measure surviving fraction
with the SRB assay, while the remainder were stained using 
the ApoAlert™ Annexin V FITC Apoptosis Kit (Clonotech
Laboratories, Palo Alto, CA) for analysis using an EPICS XL-
MCL flow cytometer (Coulter Corporation, Miami, FL). The exci-
tation wavelength was 488 nm and the detection wavelengths were
525 nm and 620 nm for AV and PI, respectively. Cells staining
negative for both markers were considered viable, since AV and PI
are membrane impermeable, while cells staining positive for
annexin V only were considered apoptotic and cells staining posi-
tive for both markers were considered necrotic. Percentages of
viable, apoptotic, and necrotic cells were determined as a function
of ascorbate concentration. 
Plasma vitamin C concentration measurements 
To analyse vitamin C pharmacokinetics during and after intra-
venous infusion, we gave a series of infusions to a 72-year-old
male who was in excellent physical condition except for slowly
progressing, non-metastatic carcinoma of the prostate. The
protocol for intravenous vitamin C infusion has been described
elsewhere (Jackson et al, 1995). Briefly, the desired amount of a
concentrated (500 mg ml–1) medical grade buffered vitamin C
solution (Steris Laboratories, Phoenix, AZ) was added to Lactated
Ringer’s solution (250 to 500 ml) and administered by a slow
intravenous ‘drip’. Venous blood samples collected before and up
to 24 hours after infusion were centrifuged to isolate plasma,1546 JJ Casciari et al 
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which was then stabilized using 3% metaphosphoric acid (4.5 ml
acid to 3 ml plasma). Plasma ascorbate concentrations were deter-
mined by reduction of 2,6-dichlorophenolindophenol (Henry et al,
1974). Infusions were given over a 2-month period, with ascorbate
doses of 15 g to 65 g and infusion times of 45 to 160 minutes.
Plasma ascorbate concentration profiles were fit to a standard 2-
compartment pharmacokinetic model (Collins, 1996). The phar-
macokinetic equations, in terms of mass action kinetics, are given
below: 
dQP = G(t) + K2QT – (K1 + KE) QP (1)
dt
dQT = K1QP – K2QT (2)
dt
Where QT represents the amount of vitamin C in the tissue
compartment and QP is the product of the plasma ascorbate
concentration and the plasma volume, which was fixed at 30 dl.
The 3 adjustable volume normalized transport parameters are: K1
(plasma to tissue), K2 (tissue to plasma), and KE (excretion). After
fitting the pharmacokinetic data to these equations and deter-
mining these rate constants, the model was used to compute the
area under the curve, an expression of ascorbate exposure, over a
one-day period. All calculations were performed using Excel
(Microsoft Corporation, Seattle, WA). 
RESULTS 
Apoptosis in SW620 HFST (Casciari et al, 1994) was confirmed in
this study by dual staining with propidium iodide and annexin V.
Cells grouped into 3 clusters; low PI and annexin V staining cells
with high forward scatter and low granularity; low PI and high
annexin V staining cells with low forward scatter and high granu-
larity; and cells with high levels of both PI and annexin V. Table 1
shows the percentages of viable, apoptotic and necrotic cells from
SW620 HFST treated with various concentrations of ascorbate.
The viable cell fractions decreased while the apoptotic and
necrotic cell fractions increased with increasing ascorbate concen-
tration. This trend was consistent with the effects of ascorbate on
surviving fraction. Ascorbate concentrations on the order of 10
mM (~200 mg dl–1) were required to kill a significant percentage
of the tumour cells. We conducted a dose–response experiment
with sodium chloride to determine what osmotic and sodium levels
SW620 HFST could tolerate. Sodium chloride concentrations of
180 mM were necessary to reduce HFST cell survival over a 2-day
period. Thus, ascorbate toxicity at 10 mM was not due to hyper-
osmotic effects. Ascorbate dose–response curves collected over a
3-year period for SW620 HFST and sparse SW620 cell popula-
tions are shown in Figure 1. The LC50 for SW620 HFST
was roughly 4 times higher than that for sparse SW620 cells, a
population comparable to exponentially growing cell monolayers.
We expect longer exposure times to decrease survival, since
surviving fraction was related to the product of concentration and
time in treatments from one hour to 48 hours (data not shown). 
To determine if cytotoxic ascorbate concentrations (on the order
of 10 mM) could be obtained in vivo, we measured plasma
concentrations with time in a volunteer during 9 intravenous ascor-
bate infusions and fit data from each infusion with a 2-compart-
ment model. The average pharmacokinetic parameter values from
9 experiments were as follows: KE = 0.025 ± 0.002 min–1, K1 =
0.35 ± 0.26 min–1 and K2 = 0.10 ± 0.07 min–1. The excretion
constant (KE) was remarkably reproducible and, while K1 and K2
had higher standard deviations, the ratio K2/K1 was also quite
reproducible (0.29 ± 0.03). Plasma vitamin C concentrations for
60 and 30 gram infusions, each over 80 minutes, are shown in
Figure 2. With 60 grams infused, plasma concentrations reached 
a maximum value of 21.8 mM (432 mg dl–1) and then slowly
decreased as the vitamin was cleared or absorbed. The resulting
area under the curve, an expression of total ascorbate exposure,
was 76 mM h over a 24 hour period. An infusion of 30 grams 
over the same time period resulted in a maximum ascorbate
concentrations of 6.6 mM (130 mg dl–1) and an area under the
curve 35 mM h. If these infusions were given consecutively 
over a 2-day period, the exposures would be 152 mM h and 
70 mM h, respectively, for the 60 and 30 gram doses. In contrast,
2-day steady state exposure to 10 mM ascorbate is equivalent to 
an area under the curve of 480 mM h–1. Since the total ascorbate
exposure obtained in vivo is lower than that necessary for 
cell killing in SW620 HFST in a 2-day period, we searched for
Table 1 Effect of 2 day treatment with vitamin C on the percentage of
viable, necrotic, and apoptotic cells in SW620 HFST. Percentages were
determined using dual staining annexin V and propidium iodide flow
cytometry. Results are compared to surviving fractions determined using the
SRB assay 
Vitamin C Flow cytometry analysis Surviving
concentration Viable Apoptotic Necrotic  fraction 
Control 63.4% 22.2% 14.3% 1.00 
3.74 mM 50.6% 29.3% 20.1% 0.84 
11.2 mM 32.8% 42.9% 24.4% 0.63 
33.7 mM 9.2% 57.6% 33.1% 0.25 
101 mM 0.9% 77.6% 21.6% 0.00 
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Figure 1 Dose–response curves for SW620 cells grown 10 days as solid
hollow fibre tumours (solid circles) or 2 days as sparse cell populations (open
circles) inside hollow fibres. Cells were treated for 2 days with vitamin C.
LC50 values of 8.4 ± 1.5 mM and 33.7 ± 2.1 mM were obtained for sparse cell
populations and HFST, respectively Antioxidant toxicity in hollow fibre tumours 1547
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antioxidants that, when used in combination with vitamin C,
would reduce the ascorbate LC50. 
LC50 values in SW620 HFST for other reagents, along with LC50
data for ascorbate when combined with these agents, are shown in
Table 2. The LC50 value of phenyl-ascorbate, a lipophilic vitamin
C analogue, was roughly 3 times lower than that of the parent
compound, suggesting that lipophilic ascorbate analogues may be
useful and that lipophilic drug delivery systems may improve
ascorbate efficacy. When combined with vitamin C, phenyl ascor-
bate increased efficacy in an additive fashion. SW620 HFST were
very sensitive to vitamin K3. In the combination treatment, vitamin
K3 decreased the ascorbate LC50 by roughly a factor of 4, though
we could not demonstrate synergy. Most interesting were the
results with lipoic acid. DL-a-lipoic acid (DL-6,8-thioctic acid) is
a lipophilic antioxidant that can be readily obtained commercially
in clinical or research reagent grade. Experiments were conducted
using both the lipophilic molecule, a form that is likely preferred
in vivo, and the sodium salt, a water-soluble form that enables
higher concentrations to be used in vitro. Both forms of lipoic acid
were toxic to SW620 HFST cells with LC50 values of roughly
3 mM. Moreover, both acted synergistically with ascorbate.
Dose–response data with ascorbate and the sodium salt of lipoic
acid are shown in Figure 3. Using a 10:1 ratio of ascorbate to
lipoic acid decreased the ascorbate LC50 to 4.5 ± 0.9 mM. This
combination killed 25% of SW620 HFST cells at an ascorbate
concentration of 1.3 mM. Exposure to ascorbate at this concentra-
tion over a 2-day period is comparable to a pharmacokinetic area
under the curve of 62 mM h, while exposure to 4.5 mM (the LC50)
over 2 days is equivalent to an area under the curve of 
216 mM h. Our pharmacokinetic data (see above) indicate that
exposures of this magnitude can be obtained in human plasma
using intravenous vitamin C infusions. 
The toxicity of ascorbic acid and lipoic acid (sodium salt) were
tested in immortalized cell monolayers of both tumour and normal
tissue origin. Results are given in Table 3. With the exception of
CCD-18Lu, the fibroblast cell lines were more resistant to these
nutrients than the tumour cell lines. The effect of cell proliferation
status on sensitivity was tested by using sparse plating densities to
allow proliferation and confluent densities to simulate quiescence.
The C/S ratio in Table 3 reflects the degree to which non-prolifer-
ating cells are more resistant than proliferating cells. Lipoic acid,
unlike ascorbate, was equally effective against both proliferating
and confluent cell monolayers, suggesting that lipoic acid may
target quiescent cells that are resistant to vitamin C. 
Because of concerns that vitamin C would protect tumour cells
from the effects of chemotherapeutic agents, we conducted exper-
iments in SW620 HFST combining sodium ascorbate with
doxorubicin. Results, shown in Figure 4, suggest that the effect of
ascorbate on doxorubicin efficacy is concentration dependent.
Ascorbate concentrations of 5 mg dl–1 (0.25 mM), an amount 
that might be relevant during oral supplementation, protected
SW620 cells from doxorubicin to a small degree, while cytotoxic
ascorbate concentrations (500 mg dl–1, or 25 mM) increased cell
killing. When ascorbate and doxorubicin were combined at a 
50 000:1 mass ratio, they had an additive but not synergistic effect,
reducing the doxorubicin LC50 by nearly 50%. For example, a
doxorubicin concentration of 0.02 mM combined with 3 mM
vitamin C would kill roughly 25% of SW620 HFST cells in 2
days, while 0.02 mM doxorubicin alone would only kill 5% of the
cells. 
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Figure 2 Vitamin C concentrations in plasma during and after an 80-minute
intravenous infusion of 60 (solid circles) or 30 (open circles) grams. The
curves represent a least squares fits of the data to the 2 compartment
pharmacokinetic model pictured in the figure inset and described in the text,
with K1, K2 and KE values of 0.31 min–1, 0.091 min–1 and 0.022 min–1 for the
60 gram infusion and 0.21 min–1, 0.060 min–1 and 0.027 min–1 for the 30 gram
infusion 
Table 2 LC50 values for 10-day-old SW620 HFST treated for 2 days with various agents, alone or in combination with sodium
ascorbate. In combination treatments, the ratio given is that of ascorbate to the agent listed. LC50 values for combination treatments
are given in terms of the ascorbate concentration. Errors are given as standard deviations. Additive values are obtained as described
in the text. Synergy was determined using Student’s t-test with standard error estimates from KaleidaGraph 
Combination therapy 
Agent Single agent LC50 (mM) Combination mass ratio Actual LC50 (mM) Additive LC50 (mM) 
Phenyl ascorbate 10.0 ± 2.5 10:1 24.6 ± 2.0 22.9 ± 2.3 
Vitamin K3 0.19 ± 0.01 40:1 7.6 ± 0.6 8.4 ± 0.8 
Lipoic acid (free acid) 3.0 ± 1.0 100:1  24.8 ± 3.0a 43.8 ± 4.2 
Lipoic acid (sodium salt) 2.6 ± 0.4 10:1  4.5 ± 0.6a 9.9 ± 1.1 
Doxorubicin 9.7 (± 1.7) ´ 10–5 50 000:1 7.3 ± 1.0 7.5 ± 0.8 
aDifferent from additive value, with 95% confidence 1548 JJ Casciari et al 
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DISCUSSION 
The results presented above lead to 4 major conclusions. First,
sodium ascorbate increases the percentage of apoptotic and
necrotic cells in SW620 HFST, though the concentrations neces-
sary for significant cell killing may not be clinically feasible.
Second, lipoic acid enhances the anti-tumor efficacy of ascorbate
to the point where significant tumour cell killing can occur at
concentrations achievable by intravenous infusion. Third, the
antioxidants lipoic acid, vitamin K3, and phenyl ascorbate are
effective against SW620 HFST in the millimolar range, suggesting
their potential use as anticancer agents. Fourth, pro-oxidant
concentrations of vitamin C do not negate the cytotoxicity of
doxorubicin, though lower ascorbate concentrations may 
protect tumour cells as well as normal tissues. These results 
indicate that the use of antioxidants, particularly ascorbate and 
lipoic acid in combination, as anti-cancer agents warrants further
study. 
Several mechanisms have been proposed by which vitamin C
may be useful in treating cancer, including speculation that it
improves immune response, reduces the severity of cachexia, and
strengthens extracellular matrix against tumour cell invasion
(Cameron et al, 1979; Henson et al, 1991). The ability of ascorbate
to kill tumour cells preferentially through hydrogen peroxide
generation has been confirmed in several in vitro studies (Bram 
et al, 1980; Leung et al, 1993) (Benade et al, 1969; Riordan et al,
1995). Rodent studies indicate that ascorbate supplementation can
inhibit tumour growth in vivo (Tsao et al, 1988; Varga and Airoldi,
1983). The present study supports a cytotoxic effect of ascorbate
with one major caveat: cells in SW620 HFST were much more
resistant to ascorbate than SW620 cell monolayers. This may
relate to the presence of quiescent cells in SW620 HFST, since
monolayer data indicate that ascorbate is less effective in treating
non-proliferating cells. Cellular transport and intra-tumor diffu-
sion may also be an issue, since the LC50 of phenyl ascorbate, a
lipophilic analogue of vitamin C, was roughly 3 times lower than
that of sodium ascorbate. 
The high concentrations of ascorbate needed for significant cell
killing led to our interest in combining it with other antioxidants.
Previous reports suggest a synergistic relationship between vita-
mins C and K3, 2 hydrogen peroxide generators, using a 100:1
molar ratio against tumour cell monolayers (Noto et al, 1989). We
failed to find a synergistic relationship using a 40:1 mass ratio 
(a roughly 55:1 molar ratio) in SW620 HFST. Proliferative and
microenvironment heterogeneity in HFST may reduce the
combined effect of the 2 agents. The use of lipoic acid in the treat-
ment of cancer has not, to our knowledge, been previously studied.
Lipoic acid is a lipophilic antioxidant that, among other things,
inhibits hydrogen peroxide generation by ascorbate in erythrocytes
(Ou et al, 1995). We were thus surprised to find that not only was
lipoic acid toxic to tumour cells at millimolar concentrations, but
that it enhanced the cytotoxicity of ascorbate in a synergistic
fashion. The reason for this synergy is unknown. Chemically, it
may relate to the ability of these nutrients to modify cellular oxida-
tion-reduction status in a manner that enhances H2O2 toxicity
(Jonas et al, 1989) or to possible ascorbate recycling by lipoic acid
in redox reactions. Biologically, the effectiveness of lipoic acid in
confluent cell monolayers suggests that it may aid in killing non-
proliferating SW620 HFST cells that are relatively resistant to
ascorbate. We do not know to what extent the effects of lipoic acid
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Figure 3 Dose–response curves for SW620 cells grown 10 days (HFST)
inside hollow fibres. Cells were treated for 2 days with vitamin C alone (open
circles LC50 = 20.4 ± 2.4 mM) or in combination the sodium salt of lipoic acid
(closed circles, LC50 = 4.3 ± 0.5 mM). The ‘additive’ curve (no points, dotted
line, LC50 = 9.8 ± 1.1 mM) represents the product of the surviving fraction for
ascorbate alone to that for lipoic acid alone, as described in the text 
Table 3 LC50 values for 7 cell lines treated for 3 days with either sodium ascorbate or the sodium salt of lipoic acid. The C/S ratio represents
the ratio of the LC50 for confluent cells to that for sparse (proliferating) cells. Cell line origins are given in the text. Errors given as standard
deviations 
Ascorbic acid (sodium salt) Lipoic acid (sodium salt) 
LC50 (mM) LC50 (mM)
Confluent Sparse Confluent Sparse
CCD-18Co no data 4.5 ± 0.9 no data  CCD-18Co no data 7.3 ± 1.5 no data 
CCD-18Lu no data 1.3 ± 0.9 no data  CCD-18Lu no data 2.2 ± 0.6 no data 
CCD-25Sk no data 7.3 ± 4.3 no data  CCD-25Sk no data 16.4 ± 2.6 no data 
SW620 5.6 ± 0.7 1.8 ± 0.3 3.1  SW620 2.8 ± 0.5 3.5 ± 0.4 0.8 
SK-MEL 2.7 ± 0.5 1.7 ± 0.3 1.6  SK-MEL 1.1 ± 0.1 2.0 ± 0.3 0.6 
Mia PaCa 5.0 ± 0.7 1.3 ± 0.2 3.8 Mia PaCa 2.7 ± 0.6 2.6 ± 0.6  1.0 
MCF-7 1.4 ± 8.5 0.6 ± 0.1 2.3  MCF-7 2.6 ± 0.3 3.3 ± 1.3 0.8 
Cell
line
C/S
ratio
Cell
line
C/S
ratioAntioxidant toxicity in hollow fibre tumours 1549
British Journal of Cancer (2001) 84(11), 1544–1550 © 2001 Cancer Research Campaign
and ascorbate on cells in SW620 HFST carry over to other solid
tumour models with different cell types and potentially different
microenvironments. However, the cytotoxicity of lipoic acid and
its effect on confluent monolayers were evident in all 4 of the
tumour cell lines we tested, and these cells had similar lipoic acid
LC50 values. 
One key in assessing the value of ascorbate anti-cancer agent is
to compare the concentrations required for tumour cell killing with
those that can be safely achieved in the clinic. In the case of ascor-
bate, we found that intravenous infusions of 30 to 60 grams could
provide plasma ascorbate exposures (area under the curve) that
would be effective against SW620 HFST if lipoic acid were also
present. The HFST model does not allow for long-term studies,
due to limited space for expansion of tumour cells. Increased treat-
ment times available in vivo should reduce the concentration
required for efficacy. Given this suggestion of feasibility, 2 key
issues arise: the relationship between plasma and tumour ascorbate
concentrations, and the safety of intravenous infusions on the
order of 50 grams. 2 lines of evidence suggest that tumour ascor-
bate levels may be higher than those in plasma. First, vitamin C
concentrations in tumours are, on the average, 3 times higher than
those in surrounding normal tissues (Langemann et al, 1989),
presumably because tumour cells use membrane glucose trans-
porters to internalize ascorbate (Agus et al, 1999). Secondly, tissue
vitamin C concentrations in guinea pigs and humans exceed those
in plasma by as much as 2 orders of magnitude (Hornig, 1975).
Vitamin C may have a favourable therapeutic index, despite the
high concentrations needed for cytotoxicity, if it accumulates in
tumours and lacks systemic toxicity. Measurements of tumour
ascorbate levels in animals given high doses of ascorbate and
lipoic acid are needed to definitively resolve this issue. 
In regards to safety, some of us (NHR, HDR) have been giving
infusions of this magnitude to patients for years (Jackson et al,
1995; Riordan et al, 1998) without ill effect. While vitamin C has
shown no major side effects in published clinical trials, the doses
used in these trials have not exceeded 10 grams per day (Cameron
and Campbell, 1974; Creagan et al, 1979). Studies at higher doses
are needed. A recent study (manuscript in preparation, Casciari JJ,
Tempero MA, Riordan NH, Rodrigues G, Taylor P, Jackson JA et
al) at the University of Nebraska indicates that blood count and
chemistry parameters are relatively stable in terminal cancer
patients given continuous infusions of up to 50 grams per day for
up to 8 weeks. We are not at this time aware of any clinical trials
testing the safety of lipoic acid at high doses. 
The accumulation of ascorbate in tumours has raised fears
among some that it may protect tumour cells from oxidative
damage associated with traditional therapeutic modalities (Raloff,
2000). However, studies in cell culture suggest that vitamin C can
enhance the efficacy of chemotherapy (Kurbacher et al, 1996) and
in vivo data suggest the same for radiation (Taper et al, 1996). In
fact, the data by Kurbacher and co-workers testing doxorubicin
efficacy in cell monolayers suggest synergy with vitamin C at 1 mM
or 0.1 mM. Our data with SW620 HFST suggest that ascorbate
protects tumour cells from doxorubicin at low concentrations (0.25
mM). This discrepancy may relate to the different models used.
Drug concentrations in monolayer experiments are straightforward,
while HFST can contain significant drug concentration gradients
(Casciari et al, 1994). It may be that the ‘protective’ effects of
ascorbate observed in HFST occur in the inner regions, where
doxorubicin and perhaps ascorbate uptake is lower than at the
proliferating rim. Also, the effects may be cell line dependent, as
Kurbacher and co-workers used breast cell lines while we used a
colon cell line. Our data suggest that pro-oxidant ascorbate concen-
trations relevant during intravenous infusions above 10 grams will
add to rather than negate the tumour cell killing of doxorubicin. To
properly resolve this issue, though, we must learn more about the
actual ascorbate and doxorubicin concentrations in solid tumours
during chemotherapy and vitamin supplementation. Moreover, we
must balance the potential negative effects of ascorbate on doxoru-
bicin efficacy against potential benefits such as alleviation of
vitamin C depletion, restoration of immune system function and
protection of normal tissues from therapeutic side effects. 
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